Vanqua Bio to Present at Upcoming Scientific Conferences
Vanqua Bio GBA1 Conference Presentation Information:
Title: VQ-101, A Small Molecule Allosteric Activator of Glucocerebrosidase (GCase) Demonstrates Robust And Sustained Target Engagement In Humans
Session date and time: June 5th 11:00am EDT
Presenter: Dr. Dan Ysselstein, Head of Biology
Vanqua Bio EAN Conference ePresentation Information:
Title: The allosteric activator of glucocerebrosidase, VQ-101, shows sustained activation of lysosomal GCase in humans
Session date and time: June 23rd 2:30pm EEST
Presenter: Dr. Maurizio Facheris, CMO
About VQ-101
VQ-101 is a novel, orally administered, fully CNS-penetrant allosteric activator of glucocerebrosidase (GCase). VQ-101 is initially being investigated in GBA-Parkinson's (GBA-PD) and idiopathic Parkinson's disease (iPD). By restoring GCase activity to healthy levels, VQ-101 aims to address the underlying genetic mechanism of disease in GBA-PD and slow or stop the progression of disease. Initial Phase 1 results with VQ-101 demonstrated sustained lysosomal GCase activation in healthy volunteers by more than 75%. In preclinical studies in patient derived neurons, 50%+ GCase activation resulted in significant blockage of the accumulation of alpha synuclein, the pathogenic hallmark of PD. A Phase 1b study in patients with PD, with and without GBA mutations, is ongoing.
About Vanqua Bio
Founded in 2019 and headquartered in Chicago, Vanqua Bio is a biopharmaceutical company dedicated to discovering and developing next-generation medicines that have the potential to transform the lives of patients with neurodegenerative and inflammatory diseases. Our technology platform utilizes human genetics and patient-derived CNS cells to identify, validate, and clinically translate novel disease pathways associated with lysosomal dysfunction or aberrant activation of the innate immune system. Initially, we are targeting glucocerebrosidase (GCase) as a potential treatment for Parkinson's disease (PD). Additional programs address overactivation of the innate immune system in peripheral and central inflammatory disorders, including renal, dermatologic and neurodegenerative diseases. For more information, go to www.vanquabio.com.
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
35 minutes ago
- Hamilton Spectator
Absorb Software's 2025 Upskilling Report Reveals Execution Gap, Underscores Strategic Learning as Key to Business Growth
CALGARY, Alberta, July 23, 2025 (GLOBE NEWSWIRE) — Absorb Software , the leading global AI-driven learning platform provider, today released its 2025 Inside the State of Upskilling report at a pivotal moment for HR, learning and development (L&D). The findings reveal a growing divide between intent and impact: while upskilling is widely acknowledged as critical to performance and resilience, most organizations struggle to implement it effectively at scale. The 2025 report offers a sharp look at the execution gap in HR and L&D. While upskilling has overtaken compliance as the top L&D priority, the report finds that most programs remain misaligned with business needs—limited by manual processes, outdated infrastructure, and fragmented ownership. Based on a survey of and insights from over 1,300 learning and HR professionals, the report examines what's working, what's not, and what's next in workforce upskilling—offering a practical framework for turning learning into a business advantage. 'Upskilling is no longer a nice-to-have—it's a business imperative,' said Kimberly Williams, CEO of Absorb Software. 'But intent alone doesn't move the needle. What's needed now is strategic learning: a system built to scale, adapt, and prove impact. 'At Absorb, we're meeting this moment with purpose-built innovation. Our AI-powered Strategic Learning System delivers scalable, hyper-personalized, and measurable learning experiences that drive real business impact—helping our customers close skills gaps faster, boost engagement, and align learning with strategic priorities.' According to the 2025 report, several macro-trends are shaping the future of L&D: As AI and Complexity Rise, Strategic Learning Takes Center Stage As hybrid work, rapid technological change, and evolving skill demands reshape the workforce, organizations face growing pressure to deliver scalable yet tailored learning. While most recognize the strategic importance of upskilling, they struggle with implementation due to each organization's unique requirements. Many rely on static tools and disconnected systems that fail to adapt training to real-world business needs—especially across diverse and evolving job roles. Even when upskilling programs are eventually launched, sustained adoption often lags—underscoring the need for systems that can personalize learning at scale and evolve with the business. Absorb's Strategic Learning System (SLS) is purpose-built to solve this challenge, helping organizations move from fragmented training efforts to connected, outcome-driven learning. Powered by AI, SLS maps critical skills, identifies individual gaps, and generates personalized learning paths tailored to specific roles—helping teams upskill at scale, even across the long tail of specialized roles. 'AI is allowing us to finally enable upskilling at scale,' said Saravana Sivanandham, Chief Marketing Officer at Absorb Software. 'Upskilling isn't a one-size-fits-all solution—that's why many past efforts have fallen short. At Absorb, we're using AI to gain a deeper understanding of the unique roles, skills, competencies, and learning paths that vary across organizations. Combined with our Strategic Learning Playbooks, this AI-driven approach helps overcome executional challenges and ensures upskilling efforts deliver measurable impact for our customers.' Strategic Learning Playbooks (SLPs) are aimed at providing a blueprint to guide the design, implementation, execution, and measurement of learning programs across a variety of learning use cases in an organization. The Path Forward: From Reactive to Strategic Learning These shifts mark a turning point for L&D. The days of disconnected programs and generic content are giving way to strategic, outcome-driven systems—powered by AI and built for scale. For organizations ready to modernize, the opportunity has never been clearer: 'Absorb's vision is to help organizations turn skills into a strategic advantage,' added Sivanandham. 'Today's learning programs must go beyond intent—they must deliver impact. That means aligning learning with business outcomes, empowering learners with the right tools, and using data to scale what works. Our position as the fastest-growing LMS provider—scaling at three times the pace of our nearest competitor—isn't just about numbers. It reflects a market shift toward measurable, AI-powered learning that drives real business results. Absorb is proud to lead that transformation.' To access the full report, please visit 2025 Inside the State of Upskilling report. Absorb Software Absorb Software is the leading global AI-driven learning platform provider, helping organizations unlock the full potential of their workforce. With its innovative Strategic Learning Systems (SLS) approach, Absorb empowers businesses to align learning with strategic goals, driving measurable impact and workforce agility. The Absorb LMS platform delivers personalized, scalable, and engaging learning experiences for employees, customers, and partners worldwide. Trusted by over 3,400 organizations and 34 million users, Absorb is redefining the future of workplace learning through cutting-edge AI, seamless integrations, and an unwavering commitment to innovation. Media Contact Zamira Tasneem Senior Communications Manager
CNBC
an hour ago
- CNBC
Healthy Returns: Researchers move closer to a universal cancer vaccine
A universal cancer vaccine – what once seemed like a pipe dream – may be inching closer to becoming reality. On Friday, University of Florida researchers said findings from a new study could lead to the development of a universal shot that can jumpstart the immune system to fight cancer. The study in mice, published in Nature Biomedical Engineering, showed that an experimental mRNA vaccine boosted the tumor-fighting effects of a common cancer drug called immune checkpoint inhibitors. The vaccine is not designed for a specific virus or cancer cells, but engineered to "wake up" the immune system against the disease, "spurring it to respond as if fighting a virus," according to a UF release. "What we found is by using a vaccine designed not to target cancer specifically but rather to stimulate a strong immunologic response, we could elicit a very strong anticancer reaction," Dr. Duane Mitchell, a co-author of the study and professor of neurosurgery at the university's College of Medicine, said in the release. That's unlike current approaches to cancer vaccines, which involve finding a target expressed by many cancer patients or, in the case of Moderna and Merck, developing personalized vaccines tailored to each patient's specific tumor. The universal vaccine has the potential to be used broadly across cancer patients, "even possibly leading us to an off-the-shelf cancer vaccine," Mitchell said. The UF researchers are still working to replicate the findings in humans. If they do, a one-size-fits-all vaccine could provide an alternative to surgery, radiation and chemotherapy. Here's how the vaccine works: The mRNA shot essentially tells the body to produce certain proteins that stimulate the immune system, including one called PD-L1, which is often found on the surface or inside of cancer cells. Those cells often use PD-L1 to hide from immune attacks. But by boosting PD-L1, the vaccine can actually make tumors more vulnerable to immune checkpoint inhibitors that block that protein, helping the immune system recognize and destroy the cancer. The study showed promising results on treatment-resistant tumors in skin cancers by combining the mRNA vaccine with a monoclonal antibody, a common immunotherapy drug that attempts to alert the immune system that a tumor is foreign and should be attacked. It also showed positive results when tested on mouse skin, bone and brain cancers as a solo treatment. In some cases, the tumors were eliminated entirely. "This paper describes a very unexpected and exciting observation: that even a vaccine not specific to any particular tumor or virus – so long as it is an mRNA vaccine – could lead to tumor-specific effects," said senior author Dr. Elias Sayour, a UF Health pediatric oncologist, in a release. Feel free to send any tips, suggestions, story ideas and data to Annika at We're just days away from the peak of digital health earnings season, and this quarter is sure to be an interesting one. The two companies that went public earlier this year, Hinge Health and Omada Health, will report results for the first time since their debut. And since President Donald Trump's tax-and-spending bill passed and his Aug. 1 tariff deadline is approaching, we'll get some insight into how digital health companies have been operating against a volatile macroeconomic and policy backdrop. Here are some of the reports CNBC will be watching for: Hinge Health – Aug. 5 Omada Health – Aug. 7 Hims & Hers Health – Aug. 4 Doximity – Aug. 7 Teladoc Health – July 29 We'll have plenty to dive into in the coming weeks, so be sure to keep up with CNBC's coverage. Feel free to send any tips, suggestions, story ideas and data to Ashley at
Chicago Tribune
an hour ago
- Chicago Tribune
What to know about Parkinson's disease after Ozzy Osbourne's death
Heavy metal rocker Ozzy Osbourne died this week at 76, just weeks after his farewell show and about five years after announcing he had Parkinson's disease. Here's what to know about the disease: Parkinson's is a neurologic disease that robs people of control over their movements. It typically starts with tremors and is characterized by slow movement, a shuffling gait, stiff limbs, balance problems and slurred speech. About 1 million Americans are living with Parkinson's, and 10 million people worldwide, the Parkinson's Foundation estimates. It usually appears after age 60, although sometimes it can develop before age 50. The exact cause isn't known, but Parkinson's develops when cells that produce one of the brain's chemical messengers, called dopamine, begin to deteriorate and die. Dopamine transports signals to parts of the brain that control movement. Parkinson's symptoms appear after enough dopamine-producing cells die that there's too little of this neurotransmitter in the brain. According to the foundation, most experts believe genetic and environmental factors are behind the disease. Dozens of gene mutations linked to Parkinson's have been discovered and genetics account for 10% to 15% of all cases. Other factors suspected of increasing the risk include head injuries, exposure to pesticides and herbicides and where you live. Ozzy Osbourne, lead singer of Black Sabbath and godfather of heavy metal, dies at 76There is no cure but there are treatments, including medications that affect dopamine levels and a surgically implanted tremor-blocking device. Patients also can benefit from physical and occupational therapy. Symptoms worsen over time, usually slowly. The severity of symptoms and how quickly they progress varies widely between patients. In advanced cases, people may be unable to walk or care for themselves. They also can suffer from depression as well as memory and thinking problems. While Parkinson's itself isn't considered fatal, people can die from complications of the disease, including lung problems as muscle weakness impedes the ability to cough and to swallow.
